<DOC>
	<DOC>NCT02410239</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).</brief_summary>
	<brief_title>MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)</brief_title>
	<detailed_description>This is a single-institution dose escalation study to determine the maximum tolerated dose (MTD) of intrathecally administered allogeneic, 3rd party mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>Age ≥ 4 years at time of study enrollment Diagnosis of ALD the diagnosis of ALD can be made by either biochemical or molecular/genetic evidence (plasma VLCFA or ABCD1 mutation analysis) supportive of ALD as the cause of cerebral demyelination Evidence of active cerebral disease defined as the presence of gadolinium enhancement on a single brain MRI study MRI used for eligibility determination may be performed at an outside institution; the most recent MRI used to determine eligibility must be within 2 calendar months of the date of enrollment on this study ALD MRI (Loes) score ≥ 10 Off of Nacetylcysteine, systemic immunosuppressive drugs or any other therapeutic intervention (except hydrocortisone and/or fludracortisone for the treatment of adrenal insufficiency) for ≥ 10 days prior to the first ITMSC dose Life expectancy of &gt;6 months as determined by the enrolling researcher and documented in the medical record Voluntary written consent provided by parent(s)/guardian(s) A candidate for allogeneic hematopoietic stem cell transplantation as determined by the University of Minnesota Inherited Metabolic and Storage Disease group Inability to undergo sedation, lumbar puncture or MRI studies for any reason Inability to stay in Minnesota for therapy through the day 28 evaluation</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cerebral Adrenoleukodystrophy</keyword>
	<keyword>cALD</keyword>
</DOC>